SISRAM MED (01696) announced that its re-licensed DaxibotulinumtoxinA-lanm injection (domestic trademark: Daxifei®, English trademark: DAXXIFY®, project code: RT002, hereinafter referred to as "Daxifei") has passed the quality standards inspection conducted by the National Institutes for Food and Drug Control (NIFDC) of China. This product is indicated for the temporary improvement of moderate to severe glabellar lines in adults associated with corrugator and/or procerus muscle activity. As of the date of this announcement, no DaxibotulinumtoxinA product is commercially available for sale within China. Passing this inspection signifies that Daxifei has met the stringent requirements for quality, safety, and efficacy set by China's national drug regulatory authorities. The company has already secured its first batch of commercial order agreements for Daxifei in the Chinese market, officially marking its entry into the commercialization implementation phase. The company believes that Daxifei, serving as a strategic cornerstone for its injectable filler business, will enrich the diversity of its product portfolio, providing more high-quality options for beauty seekers, and will act as a second growth engine, generating sustainable consumable revenue for the company and consolidating its leading position in the global beauty and wellness industry.